Gara Jalqabaatti › Leukemia Myeloidii Hamaa › Texas
Qorannoo klinikaalii Leukemia Myeloidii Hamaa Texas keessatti
Qorannoo 94 Leukemia Myeloidii Hamaa f Texas keessatti hirmaatuu jiru.
Magaalota Texas keessatti
- HoustonQorannoo 85
- DallasQorannoo 21
- AustinQorannoo 5
- San AntonioQorannoo 5
- Fort WorthQorannoo 4
- Corpus ChristiQorannoo 3
Takkalaa qorannoo (Ingiliffa)
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
- Ben Taub General Hospital, Houston
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 05-Onk-2026 · NCT05564390A Study to Assess Adverse Events and How Intravenous (IV) Pivekimab Sunirine Moves Through the Body in Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)
- Children's Medical Center Dallas /ID# 275930, Dallas
Namoota walitti qabaa jiraSadarkaa 1
6 Months – 17 Years · Saalaa hunda · Haaromfame 05-Onk-2026 · NCT07306832Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid Leukemia
- M D Anderson Cancer Center, Houston
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 50 fi ol · Saalaa hunda · Haaromfame 05-Onk-2026 · NCT03586609A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)
- The University of Texas MD Anderson Cancer Center /ID# 279402, Houston
Namoota walitti qabaa jiraSadarkaa 2/3
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 02-Onk-2026 · NCT07581002Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- The Don and Sybil Harrington Cancer Center, Amarillo
- UT MD Anderson Cancer Center, Houston
- Audie L Murphy VA Hospital, San Antonio
Namoota walitti qabaa jiraQorannoo ilaalaaHojjettoota fayyaa simatamoo
Umuriin 40 hanga 75 · Saalaa hunda · Haaromfame 02-Onk-2026 · NCT05334069Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
- Texas Children's Hospital, Houston
Namoota walitti qabaa jiraQorannoo ilaalaa
Umuriin 0 hanga 38 · Saalaa hunda · Haaromfame 01-Onk-2026 · NCT06131801A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
- University of Texas MD Anderson Cancer Center, Houston
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 12 hanga 78 · Saalaa hunda · Haaromfame 29-Ful-2026 · NCT03802695Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
- Ben Taub General Hospital, Houston
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 hanga 59 · Saalaa hunda · Haaromfame 28-Ful-2026 · NCT05554393Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
- M D Anderson Cancer Center, Houston
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 25-Ful-2026 · NCT03629171A Phase 1B/2A Trial of NADUNOLIMAB in Combination With Azacitidine (With/Without Venetoclax) in Patients With Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)
- MD Anderson Cancer Center, Houston
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 25-Ful-2026 · NCT06548230Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation
- Clinical Trial Site, Houston
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 12 fi ol · Saalaa hunda · Haaromfame 25-Ful-2026 · NCT07211958A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
- Baylor University Medical Center, Dallas
- Houston Methodist Cancer Center, Houston
- MD Anderson Cancer Center, Houston
- fi 2 dabalataa
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 25-Ful-2026 · NCT06852222Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
- M D Anderson Cancer Center, Houston
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 24-Ful-2026 · NCT03661307Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 24-Ful-2026 · NCT03874052A Phase I-II Study Investigating the All-Oral Combination of the Menin Inhibitor SNDX-5613 With Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)
- M D Anderson Cancer Center, Houston
Namoota walitti qabaa jiraSadarkaa 1/2Hojjettoota fayyaa simatamoo
Umuriin 12 fi ol · Saalaa hunda · Haaromfame 23-Ful-2026 · NCT05360160Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
- Ben Taub General Hospital, Houston
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 22-Ful-2026 · NCT06317649Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia
- M D Anderson Cancer Center, Houston
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 18-Ful-2026 · NCT03214562Dose Escalation and Expansion of Ziftomenib in Combination With Quizartinib in Acute Myeloid Leukemia
- The University of Texas M. D. Anderson Cancer Center, Houston
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 18-Ful-2026 · NCT06769490A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib
- MD Anderson Cancer Center, Houston
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 12 fi ol · Saalaa hunda · Haaromfame 18-Ful-2026 · NCT06284486Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
- M D Anderson Cancer Center, Houston
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 1 fi ol · Saalaa hunda · Haaromfame 18-Ful-2026 · NCT03630991A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
- Dell Children's Medical Center of Central Texas, Austin
- Driscoll Children's Hospital, Corpus Christi
- Medical City Dallas Hospital, Dallas
- fi 9 dabalataa
Namoota walitti qabaa jiraSadarkaa 3
6 Months – 21 Years · Saalaa hunda · Haaromfame 17-Ful-2026 · NCT04293562Clinical Study of Anti-FLT3 CAR-T Cells for the Treatment of Relapsed/Refractory AML
- MD Anderson, Houston
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 12 fi ol · Saalaa hunda · Haaromfame 17-Ful-2026 · NCT06786533Chimeric Antigen Receptor Treatment Targeting CD70 (SEVENTY)
- Texas Children's Hospital, Houston
- The Methodist Hospital, Houston
Namoota walitti qabaa jiraSadarkaa 1
Hanga umuriin 75 · Saalaa hunda · Haaromfame 16-Ful-2026 · NCT06345027Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
- The Methodist Hospital Research Institute, Houston
- The University of Texas MD Anderson Cancer Center, Houston
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 16-Ful-2026 · NCT06824168(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
- The University of Texas MD Anderson Cancer Center, Houston
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 15-Ful-2026 · NCT04996875Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
- M D Anderson Cancer Center, Houston
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 14-Ful-2026 · NCT03471260Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation
- M D Anderson Cancer Center, Houston
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 14-Ful-2026 · NCT03683433A Study of BGB-11417 in Participants With Myeloid Malignancies
- Md Anderson Cancer Center, Houston
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 14-Ful-2026 · NCT04771130A Phase Ib Study of Rezatapopt in Combination With Azacitidine in Patients With TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome)
- The University of Texas MD Anderson Cancer Center, Houston
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 11-Ful-2026 · NCT06616636A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)
- MD Anderson Cancer Center, Houston
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 11-Ful-2026 · NCT06969430A Phase Ia/Ib Open-label, Multiple Dose, Study to Determine the Recommended Dose, Evaluate PKs, PDs, Safety, and Activity of Venetoclax in Combination With Oral Decitabine/Cedazuridine (ASTX727) in Pediatric Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)
- MD Anderson Cancer Center, Houston
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 2 hanga 18 · Saalaa hunda · Haaromfame 04-Ful-2026 · NCT06191978ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
- M D Anderson Cancer Center, Houston
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 04-Ful-2026 · NCT05010122Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
- M D Anderson Cancer Center, Houston
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 12 fi ol · Saalaa hunda · Haaromfame 04-Ful-2026 · NCT03383575Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia
- Dell Children's Medical Center of Central Texas, Austin
- Driscoll Children's Hospital, Corpus Christi
- Medical City Dallas Hospital, Dallas
- fi 1 dabalataa
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 1 hanga 25 · Saalaa hunda · Haaromfame 04-Ful-2026 · NCT07022678Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
- Baylor Scott & White Health, Dallas
- MD Anderson, Houston
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 12 fi ol · Saalaa hunda · Haaromfame 03-Ful-2026 · NCT04588922Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML
- US-Dallas TX-SOUTHWESTERN, Dallas
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 02-Ful-2026 · NCT06652438CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF)
- The University of Texas MD Anderson Cancer Center, Houston
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 hanga 85 · Saalaa hunda · Haaromfame 26-Hag-2026 · NCT06834282CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
- M D Anderson Cancer Center, Houston
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 25-Hag-2026 · NCT04493164Monitoring, Detoxifying, and Rebalancing Metals During Acute Myeloid Leukemia (AML) Therapy, a Phase 2 Randomized Study
- The University of Texas M. D. Anderson Cancer Center, Houston
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 25-Hag-2026 · NCT06811233Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML
- MD Anderson Cancer Center, Houston
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 25-Hag-2026 · NCT06533761Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.